Over the past 5 years, a number of notable research advances have been made in the field
of neuroendocrine cancer, specifically with regard to neuroendocrine cancer of the …

Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …

Gastrinomas are neuroendocrine neoplasms (NENs), that occur primarily in the duodenum
and pancreas, which ectopically secrete gastrin, resulting in the Zollinger-Ellison syndrome …

Colon adenocarcinoma (COAD) is among the most prevalent cancers worldwide, ranking as
the third most prevalent malignancy in incidence and mortality. The somatostatin receptor …

Simple Summary Tumor resistance, both primary and acquired, is leading to increased
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …

Background. Functional pancreatic neuroendocrine neoplasms (PanNENs) are very rare
disorders but have complex spectrum, including insulinoma, gastrinoma, glucagonoma …

Peptide receptor radionuclide therapy (177Lu‐DOTATATE) causes DNA strand breaks and
has been validated for well‐differentiated neuroendocrine tumor treatment. Poly‐(ADP …

The process of post-transcriptional regulation has been recognized to be significantly
impacted by the presence of N 6-methyladenosine (m6A) modification. As an m6A …

Background Gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) comprise a
heterogeneous disease group. Factors that affect long‐term survival remain uncertain …

Simple Summary Tumors of colon and rectum other than adenocarcinomas represent a
neglected issue from clinical and laboratory points of view because of their rarity. In this …